Core Viewpoint - Guichuang Tongqiao (02190) has issued a positive profit forecast for the year 2025, expecting a significant increase in net profit and revenue compared to the previous year [1] Group 1: Financial Performance - The company anticipates a net profit exceeding RMB 240 million for 2025, representing a substantial year-on-year growth of approximately 139.4% [1] - Revenue is expected to surpass RMB 1.05 billion, reflecting a year-on-year increase of about 34.6% [1] Group 2: Product Performance - Sales of core products such as the Qilin blood flow guiding device, neurovascular guide wire, UltraFree drug-eluting PTA balloon catheter, and ZYLOX Swan intravascular radiofrequency closure catheter have all experienced rapid growth [1] Group 3: International Expansion - The company has achieved a significant breakthrough in its international strategy, with sales channels covering 83 countries and regions globally and over 80 strategic partnerships established with overseas partners [2] - By the end of 2025, the company plans to further expand its presence in Europe and the global market through the strategic acquisition of the German company Optimed [2] - The collaboration between production bases in China and Germany is expected to enhance global operational and delivery capabilities [2]
归创通桥盈喜后涨超5% 预期25年度净利同比增近1.4倍 国际化战略实现关键突破